硼替佐米、来那度胺和地塞米松 (VRd) 后接 Cilta-cel 的研究,这是一种针对 BCMA 的 CAR-T 疗法,对比 VRd 后接来那度胺和地塞米松 (Rd) 疗法,用于未计划进行 ASCT 的新诊断多发性骨髓瘤参与者初步治疗 (CARTITUDE-5)
一项比较硼替佐米、来那度胺和地塞米松 (VRd) 随后是 Ciltacabtagene Autoleucel 的 3 期随机研究,这是一种针对 BCMA 的嵌合抗原受体 T 细胞 (CAR-T) 疗法,对比硼替佐米、来那度胺和地塞米松 (VRd) 随后是来那度胺和地塞米松 ( Rd) 未计划将造血干细胞移植作为初始治疗的新诊断多发性骨髓瘤参与者的治疗
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).
研究概览
地位
条件
详细说明
Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the production of monoclonal immunoglobulin (Ig) proteins or protein fragments (M proteins) that have lost their function. JNJ-68284528 (ciltacabtagene autoleucel [cilta-cel]) is an autologous chimeric antigen receptor T cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. The primary hypothesis of this study is that in participants with newly diagnosed MM, treatment with VRd induction followed by a single administration of cilta-cel will significantly improve progression free survival compared to Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by Rd maintenance. The study will screen participants with newly diagnosed MM who are not planned to receive autologous stem cell transplant (ASCT) as initial therapy. This study will be conducted in 4 phases: Screening (up to 28 days), Pre-randomization Treatment, Treatment, and Follow-up. Assessments like patient-reported outcome(s) (PROs), electrocardiogram (ECG), vital signs and pharmacokinetics will be performed during the study. Safety evaluations will include review of adverse events, laboratory test results, vital sign measurements, physical examination findings, assessment of cardiac function, Immune-Effector Cell-Associated Encephalopathy (ICE) and handwriting assessments (only for Arm B) and Eastern Cooperative Oncology Group (ECOG) performance status. Safety data will be periodically reviewed by an Independent Data Monitoring Committee (IDMC). The duration of the study is approximately 12 years 5 months.
研究类型
注册 (实际的)
阶段
- 第三阶段
扩展访问
联系人和位置
学习地点
-
-
-
Aarhus N、丹麦、8200
- Aarhus University Hospital
-
Copenhagen、丹麦、2100
- Rigshospitalet
-
Odense C、丹麦、5000
- Odense Universitetshospital
-
-
-
-
-
Jerusalem、以色列、P.O.B. 120
- Hadassah University Hospita Ein Kerem
-
Ramat Gan、以色列、52621
- Sheba Medical Center Tel Hashomer
-
Tel Aviv、以色列、64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
Alberta
-
Calgary、Alberta、加拿大、T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 1M9
- Vancouver General Hospital
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8V5C2
- Juravinski Cancer Centre
-
Toronto、Ontario、加拿大、M5G2M9
- Princess Margaret Cancer Centre University Health Network
-
-
Quebec
-
Montreal、Quebec、加拿大、H1T 2M4
- Hopital Maisonneuve Rosemont
-
-
-
-
-
Budapest、匈牙利、1097
- Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
-
Debrecen、匈牙利、4032
- Debreceni Egyetem Klinikai Kozpont
-
-
-
-
-
Graz、奥地利、8036
- Medizinische Universitat Graz, LKH-Univ.Klinikum Graz, Klinische Abteilung für Hämatologie
-
Linz、奥地利、4020
- Krankenhaus der Elisabethinen Linz
-
Salzburg、奥地利、5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna、奥地利、1090
- Medical University of Vienna Universitatsklinik fur Innere Medizin I
-
-
-
-
-
Salvador、巴西、41253-190
- IDOR - Regional Bahia
-
São Paulo、巴西、01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、巴西、05651-901
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
-
-
-
-
Athens、希腊、11528
- Alexandra General Hospital of Athens
-
Athens、希腊、12462
- Attikon University General Hospital of Attica
-
Thessaloniki、希腊、57010
- G.Papanikolaou
-
-
-
-
-
Berlin、德国、12203
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin
-
Dresden、德国、01307
- Universitaetsklinikum Carl Gustav Carus TU Dresden
-
Freiburg im Breisgau、德国、79106
- Universitatsklinikum Freiburg
-
Hamburg、德国、20246
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg、德国、69120
- Universitaetsklinikum Heidelberg
-
Leipzig、德国、04103
- Universitaetsklinikum Leipzig
-
Mainz、德国、55131
- Universitatsmedizin der Johannes Gutenberg Universitat Mainz
-
München、德国、81377
- Klinikum Grosshadern Der Ludwig-Maximilians-Universitat
-
Regensburg、德国、93053
- Universitaetsklinikum Regensburg
-
Tübingen、德国、72076
- Klinikum der Eberhard Karls Universitaet Abt fur innere Med II Haematologie Onkologie Germany
-
Würzburg、德国、97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Oslo、挪威、0372
- Oslo universitetssykehus HF, Rikshospitalet
-
-
-
-
-
Brno、捷克语、625 00
- Fakultni nemocnice Brno
-
Hradec Králové、捷克语、500 05
- Fakultni nemocnice Hradec Kralove
-
Ostrava - Poruba、捷克语、708 52
- Fakultni Nemocnice Ostrava
-
Prague、捷克语、128 08
- Vseobecna fakultni nemocnice v Praze
-
-
-
-
-
Bunkyō City、日本、113 8431
- Juntendo University Hospital
-
Fukuoka、日本、812 8582
- Kyushu University Hospital
-
Hyôgo、日本、663-8501
- Hyogo Medical University Hospital
-
Kanazawa、日本、920 8641
- Kanazawa University Hospital
-
Kyoto、日本、602-8566
- University Hospital Kyoto Prefectural University of Medicine
-
Nagoya、日本、467 8602
- Nagoya City University Hospital
-
Okayama、日本、700 8558
- Okayama University Hospital
-
Sapporo、日本、060-8648
- Hokkaido University Hospital
-
Sendai、日本、980 8574
- Tohoku University Hospital
-
Shibuya City、日本、150-8935
- Japanese Red Cross Medical Center
-
-
-
-
-
Antwerp、比利时、2650
- Universitair Ziekenhuis - Antwerpen
-
Bruges、比利时、8000
- AZ St.-Jan Brugge-Oostende AV
-
Ghent、比利时、9000
- UZ Gent
-
Leuven、比利时、3000
- UZ Leuven
-
Liège、比利时、B-4000
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
-
-
-
-
Lille、法国、59000
- Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez
-
Nantes、法国、44093
- C.H.U. Hotel Dieu - France
-
Paris、法国、75475
- Hopital Saint Louis
-
Poitiers、法国、86021
- CHU Poitiers - Hopital la Miletrie
-
Toulouse、法国、31059
- Institut Universitaire du cancer de Toulouse-Oncopole
-
-
-
-
-
Gdansk、波兰、80 214
- Uniwersyteckie Centrum Kliniczne
-
Gliwice、波兰、44102
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach
-
Lublin、波兰、20 090
- Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
-
Poznan、波兰、60 569
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
Warsaw、波兰、02 776
- Instytut Hematologii i Transfuzjologii
-
Wroclaw、波兰、50 367
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
-
-
-
-
-
Camperdown、澳大利亚、2050
- Royal Prince Alfred Hospital
-
Fitzroy、澳大利亚、3065
- St Vincents Hospital Melbourne
-
Heidelberg、澳大利亚、3084
- Austin Health
-
Herston、澳大利亚、4029
- Royal Brisbane and Womens Hospital
-
Melbourne、澳大利亚、3004
- Alfred Health
-
Melbourne、澳大利亚、8006
- Peter MacCallum Cancer Centre
-
Murdoch、澳大利亚、6150
- Fiona Stanley Hospital
-
Waratah、澳大利亚、2298
- Calvary Mater Newcastle Hospital
-
Westmead、澳大利亚、2145
- Western Sydney Local Health District
-
-
-
-
-
Dublin、爱尔兰、D08 NHY1
- St James Hospital
-
-
-
-
-
Gothenburg、瑞典、413 45
- Sahlgrenska University Hospital
-
Linköping、瑞典、58185
- Universitetssjukhuset
-
Lund、瑞典、221 85
- Skane University Hospital
-
-
-
-
-
Basel、瑞士、4031
- Universitatsspital Basel
-
Bern、瑞士、3010
- Inselspital Universitatsspital Bern
-
Sankt Gallen、瑞士、9007
- Kantonsspital St Gallen
-
-
-
-
California
-
San Francisco、California、美国、94143
- UCSF
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- Yale Cancer Center
-
-
Florida
-
Miami、Florida、美国、33136
- University of Miami Health System
-
Orlando、Florida、美国、32832
- AdventHealth Cancer Institute
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa Hospitals and Clinics
-
-
Kentucky
-
Lexington、Kentucky、美国、40536-0293
- University of Kentucky
-
Louisville、Kentucky、美国、40207
- Norton Cancer Institute
-
-
Maryland
-
Baltimore、Maryland、美国、21201-1595
- University Of Maryland Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Beth Israel Deaconess Medical Center
-
-
Michigan
-
Detroit、Michigan、美国、48201
- Barbara Ann Karmanos Cancer Institute
-
Detroit、Michigan、美国、48202-2608
- Henry Ford Cancer Institute
-
-
New York
-
New York、New York、美国、10032
- Columbia University Medical Center
-
New York、New York、美国、10065
- Memorial Sloan-Kettering Cancer Center
-
New York、New York、美国、10065
- New York Presbyterian-Weill Cornell Medical College
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- Levine Cancer Institute
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19107
- Thomas Jefferson University
-
Pittsburgh、Pennsylvania、美国、15232
- University of Pittsburgh Medical Center
-
-
Virginia
-
Charlottesville、Virginia、美国、22903
- University of Virginia
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- Medical College Of Wisconsin
-
-
-
-
-
Helsinki、芬兰、00290
- Helsinki University Hospital
-
Oulu、芬兰、90220
- Oulu University Hospital
-
Turku、芬兰、20520
- Turku University Hospital
-
-
-
-
-
Birmingham、英国、B15 2TH
- University Hospitals Birmingham NHS Trust,
-
Bristol、英国、BS2 8BJ
- Bristol Royal Infirmary
-
Leeds、英国、LS9 7TF
- Leeds Teaching Hospitals NHS Trust
-
London、英国、SE5 9RS
- Kings College Hospital
-
London、英国、NW1 2BU
- University College Hospital
-
Manchester、英国、M13 9WL
- Manchester Royal Infirmary
-
Surrey、英国、SM2 5PT
- The Royal Marsden NHS Trust Sutton
-
-
-
-
-
Amsterdam、荷兰、1081 HV
- VU Medisch Centrum
-
Groningen、荷兰、9713 GZ
- University Medical Center Groningen
-
Nijmegen、荷兰、6500 HB
- UMC Radboud
-
Rotterdam、荷兰、3075 EA
- Erasmus MC
-
-
-
-
-
Lisbon、葡萄牙、1099-023
- Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. 1
-
Porto、葡萄牙、4200072
- Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E.
-
-
-
-
-
Barcelona、西班牙、08041
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona、西班牙、8035
- Hosp Univ Vall D Hebron
-
L'Hospitalet de Llobregat、西班牙、08908
- Instituto Catalan Deoncologia Hospital Duran I Reynals
-
Madrid、西班牙、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、西班牙、28007
- Hosp. Gral. Univ. Gregorio Maranon
-
Murcia、西班牙、30120
- Hosp. Univ. Virgen de La Arrixaca
-
Pamplona、西班牙、31008
- Clinica Univ. de Navarra
-
Salamanca、西班牙、37007
- Hosp Clinico Univ de Salamanca
-
Santander、西班牙、39008
- Hosp. Univ. Marques de Valdecilla
-
Seville、西班牙、41013
- Hosp. Virgen Del Rocio
-
Valencia、西班牙、46026
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Buenos Aires、阿根廷、C1118AAT
- Hospital Aleman
-
Buenos Aires、阿根廷、C1199ABD
- Hospital Italiano de Buenos Aires
-
Córdoba、阿根廷、5016
- Hospital Privado Universitario De Cordoba
-
-
-
-
-
Jeollanam-do、韩国、58128
- Chonnam National University Hwasun Hospital
-
Seoul、韩国、03080
- Seoul National University Hospital
-
Seoul、韩国、05505
- Asan Medical Center
-
Seoul、韩国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韩国、06351
- Samsung Medical Center
-
Seoul、韩国、06591
- The Catholic University of Korea Seoul St Marys Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Documented diagnosis of multiple myeloma (MM) according to International Myeloma Working Group (IMWG) diagnostic criteria
- Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=)1.0 gram per deciliter (g/dL) or urine M-protein level >=200 milligram (mg)/24 hours; or Light chain MM in whom only measurable disease is by serum free light chain (FLC) levels: Serum immunoglobin (Ig) free light chain >=10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa/lambda FLC ratio
- Eastern Cooperative Oncology Group Performance Status grade of 0 or 1
- Not considered for high-dose chemotherapy with Autologous Stem Cell Transplant (ASCT) due to: Ineligible due to advanced age; or Ineligible due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT; or Deferral of high-dose chemotherapy with ASCT as initial treatment
- A woman of childbearing potential (WOCBP) must have 2 negative highly sensitive serum or urine pregnancy tests (beta-human chorionic gonadotropin) prior to starting Bortezomib, Lenalidomide and Dexamethasone (VRd) and must agree to further testing during the study.
- Clinical laboratory values meeting the following criteria during the screening phase: hemoglobin greater than or equal to (>=) 8.0 g/dL (>=5 millimoles per liter [mmol/L]), recombinant human erythropoietin use is permitted; platelets >=75 *10^9/L; absolute lymphocyte count >=0.3 *10^9/L; absolute neutrophil count (ANC) >=1.0 ×10^9/L (prior growth factor support is permitted but must be without support in the 7 days prior to the laboratory test); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to (<=) 3.0 * upper limit of normal (ULN); estimated glomerular filtration rate >=40 milliliter per minute/1.73 meter square (mL/min/1.73 m^2) based upon modified diet in renal disease formula (MDRD-4) calculation or a 24-hour urine collection; total bilirubin <=2.0 * ULN; except in participants with congenital hyperbilirubinemia, such as Gilbert syndrome (in which case direct bilirubin <=2.0 * ULN is required)
Exclusion Criteria:
- Frailty index of >=2 according to Myeloma Geriatric Assessment score
- Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5
- Known active, or prior history of central nervous system (CNS) involvement or clinical signs of meningeal involvement of MM
- Stroke or seizure within 6 months of signing Informed Consent Form (ICF)
- Seropositive for human immunodeficiency virus (HIV)
- Vaccinated with live, attenuated vaccine within 4 weeks prior to first dose of VRd
- Participant must not require continuous supplemental oxygen
- Hepatitis B infection
- Hepatitis C infection
- Prior treatment with chimeric antigen receptor T (CAR-T) therapy directed at any target
- Any therapy that is targeted to B-cell maturation antigen (BCMA)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: VRd+Rd (Standard Therapy)
Participants will receive bortezomib, lenalidomide, and dexamethasone (VRd) regimen for 6 cycles before randomization. Following randomization, participants in Arm A will receive 2 more cycles of VRd. In VRd treatment, participants will receive bortezomib 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each cycle (Cycles 1 to 8), oral lenalidomide 25 mg on Days 1 to 14 of each cycle (Cycles 1 to 8) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle (Cycles 1 to 8). Each cycle will consist of 21 days. After 8 cycles of VRd, treatment will continue with lenalidomide and dexamethasone (Rd) maintenance therapy. In Rd treatment, participants will receive oral lenalidomide 25 mg on Days 1 to 21 of each cycle and oral dexamethasone 40 mg on Days 1, 8, 15, and 22 of each cycle. Each cycle will consist of 28 days. Participants will continue to receive Rd until confirmed progressive disease or unacceptable toxicity. |
Bortezomib will be administered SC. Dexamethasone will be administered orally. Lenalidomide will be administered orally. |
|
实验性的:Arm B: VRd+Ciltacabtagene Autoleucel (Cilta-cel)
Participants will receive VRd regimen for 6 cycles before randomization. Following randomization, participants in Arm B will undergo apheresis and receive two more cycles of VRd as bridging therapy. In VRd treatment, participants will receive bortezomib 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each cycle for Cycles 1 to 8; oral lenalidomide 25 mg on days 1 to 14 of each cycle for Cycles 1 to 8 and oral dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle for Cycles 1 to 8. Each cycle will consist of 21 days. After 8 cycles of VRd, participants will receive a conditioning regimen (cyclophosphamide 300 mg/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily for 3 days) and Cilta-cel infusion 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg). |
Bortezomib will be administered SC. Dexamethasone will be administered orally. Lenalidomide will be administered orally. Cilta-cel infusion will be administered.
其他名称:
Cyclophosphamide will be administered intravenously. Fludarabine will be administered intravenously. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression Free Survival (PFS)
大体时间:Up to 4 years and 5 months
|
Progression-free survival is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD), as defined in the International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first. |
Up to 4 years and 5 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sustained Minimal Residual Disease (MRD) Negative CR
大体时间:Up to 12 years and 5 months
|
Sustained MRD negative complete response (CR) as determined by next generation sequencing (NGS) with sensitivity of 10^-5, and defined by MRD negative CR plus at least 12 months durability of the MRD negative CR status. |
Up to 12 years and 5 months
|
|
MRD Negative CR at 9 Months
大体时间:9 months
|
MRD negative CR rate at 9 months is defined as the percentage of participants who achieve MRD negative CR status at 9±3 months after the randomization date. |
9 months
|
|
Overall MRD Negative CR
大体时间:Up to 12 years and 5 months
|
Overall MRD negative is defined as the percentage of participants who achieve MRD negativity at any time after the date of randomization before initiation of subsequent therapy. |
Up to 12 years and 5 months
|
|
Overall Survival (OS)
大体时间:Up to 12 years and 5 months
|
Overall survival is measured from the date of randomization to the date of the participant's death. |
Up to 12 years and 5 months
|
|
Complete Response or Better
大体时间:Up to 12 years and 5 months
|
CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response according to the IMWG criteria. |
Up to 12 years and 5 months
|
|
Time to Subsequent Anti-myeloma Therapy
大体时间:Up to 12 years and 5 months
|
Time to subsequent anti-myeloma therapy is defined as the time from randomization to the start of subsequent anti-myeloma therapy. |
Up to 12 years and 5 months
|
|
Progression Free Survival on Next-line Therapy (PFS2)
大体时间:Up to 12 years and 5 months
|
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as PD as assessed by investigator that starts after the next line of subsequent therapy, or death from any cause, whichever occurs first. |
Up to 12 years and 5 months
|
|
Number of Participants with Adverse Events (AEs), Abnormalities in Laboratory Parameters, 12-Lead Electrocardiogram (ECG), Physical Examination, and Vital Signs
大体时间:Up to 12 years and 5 months
|
Number of participants with AEs, abnormalities in laboratory parameters (complete blood count [CBC] with differential, coagulation, chimeric antigen receptor T cell [CAR-T] chemistry, full metabolic panel etc.), 12-lead ECG, physical examination, and vital signs will be reported. |
Up to 12 years and 5 months
|
|
Arm B: Systemic Cytokine Concentrations
大体时间:Up to Day 112
|
Serum or plasma proteomic profiling of cytokines (such as interleukin [IL] 6, IL-15, and IL 10) concentrations will be measured for biomarker assessment. |
Up to Day 112
|
|
Arm B: Levels of Chimeric Antigen Receptor T cell (CAR-T) Cell Activation Markers
大体时间:Up to 12 years and 5 months
|
CAR-T cell activation markers including, but not limited to, CD4+, CD8+, CD25+, central memory, effector memory cells will be reported. An evaluation of cell populations may be performed by flow cytometry, cytometry by time of flight (CyTOF), single cell RNA sequencing (scRNAseq) or similar technologies and be correlated with response. |
Up to 12 years and 5 months
|
|
Arm B: Levels of Soluble B-cell Maturation Antigen (BCMA)
大体时间:Up to 1 year
|
Levels of soluble BCMA will be reported. |
Up to 1 year
|
|
Arm B: Levels of Cilta-cel Expansion (proliferation), and Persistence
大体时间:Up to 12 years and 5 months
|
Levels of cilta-cel expansion (proliferation), and persistence via monitoring CAR-T positive cell counts and CAR transgene level will be reported. |
Up to 12 years and 5 months
|
|
Arm B: Number of Participants with Anti-cilta-cel Antibodies
大体时间:Up to 12 years and 5 months
|
Number of participants with anti-cilta-cel antibodies will be reported. |
Up to 12 years and 5 months
|
|
Arm B: Number of Participants with Presence of Replication Competent Lentivirus
大体时间:Up to 12 years and 5 months
|
Number of participants with presence of replication competent lentivirus will be reported. |
Up to 12 years and 5 months
|
|
Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score
大体时间:Baseline up to 12 years and 5 months
|
The EORTC QLQ-C30 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The responses are reported using a verbal rating scale. The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms. |
Baseline up to 12 years and 5 months
|
|
Change from Baseline in Health-Related Quality of Life as Assessed by MySIm-Q Scale Score
大体时间:Baseline up to 12 years and 5 months
|
The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items with recall period of "7 days" and responses are reported on a 5-point verbal rating scale. Item responses are scored from 0 to 4. Higher scores indicate greater severity/impact. |
Baseline up to 12 years and 5 months
|
|
Change from Baseline in Health-Related Quality of Life as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Scale Score
大体时间:Baseline up to 12 years and 5 months
|
The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems, plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Baseline up to 12 years and 5 months
|
|
Change from Baseline in Health-Related Quality of Life as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score
大体时间:Baseline up to 12 years and 5 months
|
The PGIS uses 2 items to assess the participant's perception of the severity of their disease symptoms and impact using a 5-point verbal rating scale. Score ranges from 1 (None) to 5 (Very Severe). |
Baseline up to 12 years and 5 months
|
|
Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Items
大体时间:Up to 161 days
|
The National Cancer Institute's PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference that ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact. |
Up to 161 days
|
|
Time to Worsening of Symptoms, Functioning and Overall Well-being
大体时间:Up to 12 year and 5 months
|
Time to worsening is measured as the interval from the date of randomization to the start date of worsening in MySIm-Q symptom, impact, or total scores. |
Up to 12 year and 5 months
|
合作者和调查者
调查人员
- 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CR109015
- 2021-001242-35 (EudraCT编号)
- 68284528MMY3004 (其他标识符:Janssen Research & Development, LLC)
- 2023-505850-16-00 (注册表标识符:EUCT number)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.